APOTEX LICENSES EXCLUSIVE CANADIAN RIGHTS TO QUTENZA® FROM GRÜNENTHAL

Contributed by: News Aktuell

Issued by news aktuell/OTS on behalf of Grünenthal Group

Logo

Tags

Medical profession

Joint venture

More Like This

GRÜNENTHAL LICENSES EXCLUSIVE AUSTRALIAN RIGHTS TO QUTENZA® TO CLINECT

GRÜNENTHAL LICENSES EXCLUSIVE SOUTH KOREAN RIGHTS TO QUTENZA® TO BCWORLD PHARM

GRÜNENTHAL PRESENTS PHASE III RESULTS FOR QUTENZA® IN POST-SURGICAL NEUROPATHIC PAIN AT IASP 2026 WORLD CONGRESS ON PAIN

GRÜNENTHAL LICENSES EXCLUSIVE CANADIAN RIGHTS TO TESTOSTERONE REPLACEMENT THERAPY NEBIDO® TO APOTEX

GRÜNENTHAL PARTNERS WITH DKSH TO BRING FOUR IMPORTANT PAIN MEDICINES TO EIGHT NEW MARKETS IN ASIA-PACIFIC

QPS Neuropharmacology facility in Grambach, Austria. (Graphic: Business Wire)

QPS Holdings, LLC divests its Neuropharmacology Business Unit

PR Newswire associated0

Zentiva secures approx. 85.27% of APONTIS PHARMA AG voting rights in the context of its public purchase offer

GRÜNENTHAL TAKES FULL OWNERSHIP OF GRÜNENTHAL MEDS, THE JOINT VENTURE ESTABLISHED WITH KYOWA KIRIN FOR ITS ESTABLISHED MEDICINES BRANDS